65 resultados para Tnbs
Resumo:
L’osteoartrosi è la malattia delle articolazioni più comune al mondo ed è spesso causa di condizioni fortemente disabilitanti. Date le limitazioni dei trattamenti attualmente proposti per la gestione dei pazienti osteoartrosici è di grande interesse la ricerca di soluzioni alternative. A tal fine Fin-Ceramica S.p.A. desidera progettare un innovativo sostituto osteocondrale in collagene attivato con un’emergente classe di macromolecole polimeriche: i dendrimeri. Questi polimeri offrono un’unica opportunità di mostrare all’interfaccia con il tessuto naturale una pluralità di gruppi funzionali favorendo, con un’adeguata ingegnerizzazione, le interazioni biologiche e sostenendo la vitalità e l’attività cellulare. In questo lavoro di tesi, con in mente una futura convalida di processo necessaria a garantire la sicurezza e l’affidabilità del prodotto, sono stati sviluppati nuovi metodi per verificare ed ottimizzare la reazione di sintesi del dendrimero, per caratterizzare il materiale ottenuto e per creare legami covalenti fra collagene e dendrimero attivando potenzialmente il sostituto osteocondrale. Il primo obiettivo è stato conseguito sfruttando la presenza o l’assenza di gruppi amminici disponibili ai terminali del dendrimero in crescita e la formazione di un prodotto di scarto cromoforo durante la sintesi. In relazione a questi elementi sono stati individuati metodi semplici ed efficaci, quali la spettrofotometria ultravioletta ed i saggi colorimetrici con TNBS e ninidrina, per monitorare ogni step di reazione portandolo a compimento e ricavare i tempi necessari a tale scopo. Il dendrimero ottenuto è stato quindi caratterizzato tramite spettrometria infrarossa in trasformata di Fourier. Nota la composizione teorica della nostra macromolecola quest’analisi ha consentito l’identificazione del materiale prodotto ed ha inoltre permesso di dimostrare la ripetibilità dello specifico processo di sintesi dendrimerica. Infine per individuare una possibile procedura di funzionalizzazione del collagene con il dendrimero sono stati sperimentati due differenti metodi relativi a due diversi agenti crosslinkanti. Per rilevare un’eventuale modifica delle proprietà superficiali dei campioni realizzati, conseguente alla presenza dei dendrimeri, ne è stata valutata la bagnabilità attraverso la misura dell’angolo di contatto. La determinazione per uno dei due metodi di un significativo aumento di idrofilicità rispetto al campione di controllo ha verificato la fattibilità della reazione di funzionalizzazione del collagene con il dendrimero sintetizzato in questa ricerca identificando un possibile reagente ed una relativa procedura. I risultati ottenuti da queste ricerche costituiscono informazioni necessarie all’attività di convalida del processo di sintesi del dendrimero ed alla realizzazione del sostituto osteocondrale attivato progettato da Fin-Ceramica.
Resumo:
Transient inflammation is known to alter visceral sensory function and frequently precede the onset of symptoms in a subgroup of patients with irritable bowel syndrome (IBS). Duration and severity of the initial inflammatory stimulus appear to be risk factors for the manifestation of symptoms. Therefore, we aimed to characterize dose-dependent effects of trinitrobenzenesulfonic acid (TNBS)/ethanol on: (1) colonic mucosa, (2) cytokine release and (3) visceral sensory function in a rat model. Acute inflammation was induced in male Lewis rats by single administration of various doses of TNBS/ethanol (total of 0.8, 0.4 or 0.2 ml) in test animals or saline in controls. Assessment of visceromotor response (VMR) to colorectal distensions, histological evaluation of severity of inflammation, and measurement of pro-inflammatory cytokine levels (IL-2, IL-6) using enzyme-linked immunosorbent assay (ELISA) were performed 2h and 3, 14, 28, 31 and 42 days after induction. Increased serum IL-2 and IL-6 levels were evident prior to mucosal lesions 2h after induction of colitis and persist up to 14 days (p<0.05 vs. saline), although no histological signs of inflammation were detected at 14 days. In the acute phase, VMR was only significantly increased after 0.8 ml and 0.4 ml TNBS/ethanol (p<0.05 vs. saline). After 28 days, distension-evoked responses were persistently elevated (p<0.05 vs. saline) in 0.8 and 0.4 ml TNBS/ethanol-treated rats. In 0.2 ml TNBS/ethanol group, VMR was only enhanced after repeated visceral stimulation. Visceral hyperalgesia occurs after a transient colitis. However, even a mild acute but asymptomatic colitis can induce long-lasting visceral hyperalgesia in the presence of additional stimuli.
Resumo:
OBJECTIVE Crohn's disease is a chronic inflammatory process that has recently been associated with a higher risk of early implant failure. Herein we provide information on the impact of colitis on peri-implant bone formation using preclinical models of chemically induced colitis. METHODS Colitis was induced by intrarectal instillation of 2,4,6-trinitro-benzene-sulfonic-acid (TNBS). Colitis was also induced by feeding rats dextran-sodium-sulfate (DSS) in drinking water. One week after disease induction, titanium miniscrews were inserted into the tibia. Four weeks after implantation, peri-implant bone volume per tissue volume (BV/TV) and bone-to-implant contacts (BIC) were determined by histomorphometric analysis. RESULTS Cortical histomorphometric parameters were similar in the control (n = 10), DSS (n = 10) and TNBS (n = 8) groups. Cortical BV/TV was 92.2 ± 3.7%, 92.0 ± 3.0% and 92.6 ± 2.7%. Cortical BIC was 81.3 ± 8.8%, 83.2 ± 8.4% and 84.0 ± 7.0%, respectively. No significant differences were observed when comparing the medullary BV/TV and BIC (19.5 ± 6.4%, 16.2 ± 5.6% and 15.4 ± 9.0%) and (48.8 ± 12.9%, 49.2 ± 6.2 and 41.9 ± 11.7%), respectively. Successful induction of colitis was confirmed by loss of body weight and colon morphology. CONCLUSIONS The results suggest bone regeneration around implants is not impaired in chemically induced colitis models. Considering that Crohn's disease can affect any part of the gastrointestinal tract including the mouth, our model only partially reflects the clinical situation.
Resumo:
To clarify the role of Peyer's patches in oral tolerance induction, BALB/c mice were treated in utero with lymphotoxin β-receptor Ig fusion protein to generate mice lacking Peyer's patches. When these Peyer's patch-null mice were fed 25 mg of ovalbumin (OVA) before systemic immunization, OVA-specific IgG Ab responses in serum and spleen were seen, in marked contrast to low responses in OVA-fed normal mice. Further, high T-cell-proliferative- and delayed-type hypersensitivity responses were seen in Peyer's patch-null mice given oral OVA before systemic challenge. Higher levels of CD4+ T-cell-derived IFN-γ, IL-4, IL-5, and IL-10 syntheses were noted in Peyer's patch-null mice fed OVA, whereas OVA-fed normal mice had suppressed cytokine levels. In contrast, oral administration of trinitrobenzene sulfonic acid (TNBS) to Peyer's patch-null mice resulted in reduced TNBS-specific serum Abs and splenic B cell antitrinitrophenyl Ab-forming cell responses after skin painting with picryl chloride. Further, when delayed-type hypersensitivity and splenic T cell proliferative responses were examined, Peyer's patch-null mice fed TNBS were unresponsive to hapten. Peyer's patch-null mice fed trinitrophenyl-OVA failed to induce systemic unresponsiveness to hapten or protein. These findings show that organized Peyer's patches are required for oral tolerance to proteins, whereas haptens elicit systemic unresponsiveness via the intestinal epithelial cell barrier.
Resumo:
We have previously shown that complement factor 5a(C5a) plays a role in the pathogenesis of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats by using the selective, orally active C5a antagonist AcF-[OP(D-Cha) WR]. This study tested the efficacy and potency of a new C5a antagonist, hydrocinnamate (HC)-[OP(D-Cha) WR], which has limited intestinal lumenal metabolism, in this model of colitis. Analogs of AcF-[OP(D-Cha) WR] were examined for their susceptibility to alimentary metabolism in the rat using intestinal mucosal washings. One metabolically stable analog, HC-[OP(D-Cha)WR], was then evaluated pharmacokinetically and investigated at a range of doses (0.03 - 10 mg/kg/ day p.o.) in the 8-day rat TNBS- colitis model, against the comparator drug AcF-[OP(D-Cha) WR]. Using various amino acid substitutions, it was determined that the AcF moiety of AcF-[OP(D-Cha) WR] was responsible for the metabolic instability of the compound in intestinal mucosal washings. The analog HC-[OP( D-Cha) WR], equiactive in vitro to AcF-[OP(D-Cha) WR], was resistant to intestinal metabolism, but it displayed similar oral bioavailability to AcF-[OP(D-Cha) WR]. However, in the rat TNBS- colitis model, HC-[OP(D-Cha) WR] was effective at reducing mortality, colon edema, colon macroscopic scores, and increasing food consumption and body weights, at 10- to 30- fold lower oral doses than AcF-[OP( D-Cha) WR]. These studies suggest that resistance to intestinal metabolism by HC-[OP(D-Cha) WR] may result in increased local concentrations of the drug in the colon, thus affording efficacy with markedly lower oral doses than AcF-[OP(D-Cha) WR] against TNBS-colitis. This large increase in potency and high efficacy of this compound makes it a potential candidate for clinical development against intestinal diseases such as inflammatory bowel disease.